|Mr. Gary Jonathan Phillips BPharm, MBA||CEO, MD & Director||468.13k||N/A||1961|
|Dr. Brett Charlton MBBS Ph.D., Ph.D.||Co-Founder & Medical Director||371.57k||N/A||1956|
|Mr. David Morris McGarvey BA, CA, CPA||CFO & Company Sec.||374.6k||N/A||1956|
|Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.||Head of Drug Discovery||365.48k||N/A||1964|
|Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedSc||Alliance Management - Head of Medical & Regulatory Affairs||234.91k||N/A||1972|
|Mr. Cameron David Billingsley||Gen. Counsel||N/A||N/A||1977|
|Dr. Dieter Hamprecht||Head of Chemistry for Drug Discovery||N/A||N/A||N/A|
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting myelofibrosis and other cancers, and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Pharmaxis Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.